WO2004020631A3 - Genetic suppression and replacement - Google Patents

Genetic suppression and replacement Download PDF

Info

Publication number
WO2004020631A3
WO2004020631A3 PCT/GB2003/003793 GB0303793W WO2004020631A3 WO 2004020631 A3 WO2004020631 A3 WO 2004020631A3 GB 0303793 W GB0303793 W GB 0303793W WO 2004020631 A3 WO2004020631 A3 WO 2004020631A3
Authority
WO
WIPO (PCT)
Prior art keywords
suppression
nucleic acid
gene
replacement
replacement nucleic
Prior art date
Application number
PCT/GB2003/003793
Other languages
French (fr)
Other versions
WO2004020631A2 (en
Inventor
Gwenyth Jane Farrar
Peter Humphries
Paul Francis Kenna
Original Assignee
Optigen Technologies Ltd
Gwenyth Jane Farrar
Peter Humphries
Paul Francis Kenna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606961.2A external-priority patent/GB9606961D0/en
Application filed by Optigen Technologies Ltd, Gwenyth Jane Farrar, Peter Humphries, Paul Francis Kenna filed Critical Optigen Technologies Ltd
Priority to CA2496904A priority Critical patent/CA2496904C/en
Priority to EP03753679.4A priority patent/EP1532246B1/en
Priority to AU2003271841A priority patent/AU2003271841A1/en
Publication of WO2004020631A2 publication Critical patent/WO2004020631A2/en
Publication of WO2004020631A3 publication Critical patent/WO2004020631A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Abstract

Methods and agents for suppressing expression of a mutant allele of a gene and providing a replacement nucleic acid are provided. The methods of the invention provide suppression effectors such as, for example, antisense nucleic acids, ribozymes, or RNAi, that bind to the gene or its RNA. The invention further provides for the introduction of a replacement nucleic acid with modified sequences such that the replacement nucleic acid is protected from suppression by the suppression effector. The replacement nucleic acid is modified at degenerate wobble positions in the target region of the suppression effector and thereby is not suppressed by the suppression effector. In addition, by altering wobble positions, the replacement nucleic acid can still encode a wild type gene product. The invention has the advantage that the same suppression strategy could be used to suppress, in principle, many mutations in a gene. Also disclosed is a transgenic mouse that expresses human rhodopsin (modified replacement gene) and a transgenic mouse that expresses a suppression effector targeting rhodopsin. Also disclosed in intraocular administration of siRNA.
PCT/GB2003/003793 1996-04-02 2003-09-01 Genetic suppression and replacement WO2004020631A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA2496904A CA2496904C (en) 1996-04-02 2003-09-01 Genetic suppression and replacement
EP03753679.4A EP1532246B1 (en) 1996-04-02 2003-09-01 Genetic suppression and replacement
AU2003271841A AU2003271841A1 (en) 1996-04-02 2003-09-01 Genetic suppression and replacement

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9606961.2A GB9606961D0 (en) 1996-04-02 1996-04-02 Genetic strategy III
US09/155,708 US7138378B1 (en) 1996-04-02 1997-04-02 Genetic suppression and replacement
US40738902P 2002-08-30 2002-08-30
US60/407,389 2002-08-30
US41469802P 2002-09-30 2002-09-30
US60/414,698 2002-09-30
US10/651,754 US20040234999A1 (en) 1996-04-02 2003-08-29 Genetic suppression and replacement
US10/651,754 2003-08-29

Publications (2)

Publication Number Publication Date
WO2004020631A2 WO2004020631A2 (en) 2004-03-11
WO2004020631A3 true WO2004020631A3 (en) 2004-07-29

Family

ID=37670462

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/003793 WO2004020631A2 (en) 1996-04-02 2003-09-01 Genetic suppression and replacement

Country Status (5)

Country Link
US (1) US20040234999A1 (en)
EP (1) EP1532246B1 (en)
AU (1) AU2003271841A1 (en)
CA (1) CA2496904C (en)
WO (1) WO2004020631A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551970B2 (en) * 1996-04-02 2013-10-08 Optigen Patents Limited Genetic suppression and replacement
RU2348695C2 (en) 2006-05-23 2009-03-10 Закрытое акционерное общество "Молекулярно-медицинские технологии" Differentiating and specific oligonucleotids for dna sequence identification for infection agents in biological materials, method of species identification of infection agents, biochip and method implementation kit
JP2010500011A (en) 2006-08-08 2010-01-07 ガンサー ハートマン Structure and use of 5 'phosphate oligonucleotides
CA2678055C (en) * 2007-04-10 2016-02-16 Qiagen Gmbh Rna interference tags
CA2683469C (en) 2007-04-12 2019-11-26 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Genetic suppression and replacement
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
EP2218781A1 (en) * 2009-02-11 2010-08-18 Qiagen GmbH RNAi based selection system
WO2010124231A2 (en) * 2009-04-24 2010-10-28 The Board Of Regents Of The University Of Texas System Modulation of gene expression using oligomers that target gene regions downstream of 3' untranslated regions
WO2011019793A2 (en) * 2009-08-13 2011-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health Individualized therapy of single gene disorders with genetically modified adult stem cells
CA3102008A1 (en) 2010-06-02 2011-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
CN115896106A (en) 2016-03-01 2023-04-04 佛罗里达大学研究基金会有限公司 AAV vectors for the treatment of dominant retinitis pigmentosa
WO2022019706A1 (en) * 2020-07-24 2022-01-27 알지노믹스 주식회사 Trans-splicing ribozyme that is specific to rhodopsin transcriptome, and use thereof
KR102396200B1 (en) * 2020-07-24 2022-05-12 알지노믹스 주식회사 A trans-splicing ribozyme specific for rhodopsin transcript and uses thereof
US20220098615A1 (en) * 2020-09-30 2022-03-31 NGGT, Inc. Dual functional expression vectors and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019448A1 (en) * 1994-01-14 1995-07-20 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection in histologic tissue
WO1997032024A1 (en) * 1996-03-01 1997-09-04 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Allele suppression
WO1997037014A1 (en) * 1996-04-02 1997-10-09 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Genetic suppression and replacement
WO1998048027A2 (en) * 1997-04-21 1998-10-29 University Of Florida Materials and methods for treatment of retinal diseases
WO2003048362A2 (en) * 2001-11-30 2003-06-12 Optigen Patents Limited Suppression of polymeric alleles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5223391A (en) * 1990-02-21 1993-06-29 President And Fellows Of Harvard College Inhibitors of herpes simplex virus replication
DK51092D0 (en) * 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
US5807718A (en) * 1994-12-02 1998-09-15 The Scripps Research Institute Enzymatic DNA molecules
US6482803B1 (en) * 1995-09-01 2002-11-19 Board Of Regents, The University Of Texas System Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme A
GB9519299D0 (en) * 1995-09-21 1995-11-22 Farrar Gwyneth J Genetic strategy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019448A1 (en) * 1994-01-14 1995-07-20 The Johns Hopkins University School Of Medicine Nucleic acid mutation detection in histologic tissue
WO1997032024A1 (en) * 1996-03-01 1997-09-04 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Allele suppression
WO1997037014A1 (en) * 1996-04-02 1997-10-09 Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Genetic suppression and replacement
WO1998048027A2 (en) * 1997-04-21 1998-10-29 University Of Florida Materials and methods for treatment of retinal diseases
WO2003048362A2 (en) * 2001-11-30 2003-06-12 Optigen Patents Limited Suppression of polymeric alleles

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRUMMELKAMP T R ET AL: "A system for stable expression of short interfering RNAs in mammalian cells", SCIENCE, vol. 296, no. 5567, 19 April 2002 (2002-04-19), pages 550 - 553, XP002225638, ISSN: 0036-8075 *
LEWIN A S ET AL: "Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa", NATURE MEDICINE, vol. 4, no. 8, 1 August 1998 (1998-08-01), pages 967 - 971, XP002090346, ISSN: 1078-8956 *
MILLINGTON-WARD S ET AL: "Strategems in vitro for gene therapies directed to dominant mutations", NUCLEIC ACIDS RESEARCH, vol. 6, no. 9, September 1997 (1997-09-01), pages 1415 - 1426, XP002254680, ISSN: 0305-1048 *
O'NEILL BRIAN ET AL: "Ribozyme-based therapeutic approaches for autosomal dominant retinitis pigmentosa", IOVS, vol. 41, no. 10, September 2000 (2000-09-01), pages 2863 - 2869, XP002281307 *
TOUDJARSKA I ET AL: "Delivery of a hammerhead ribozyme specifically downregulates mutant type I collagen mRNA in a murine model of osteogenesis imperfecta", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, vol. 11, no. 5, October 2001 (2001-10-01), pages 341 - 346, XP002254679, ISSN: 1087-2906 *

Also Published As

Publication number Publication date
US20040234999A1 (en) 2004-11-25
AU2003271841A8 (en) 2004-03-19
EP1532246B1 (en) 2018-07-11
CA2496904C (en) 2014-12-09
EP1532246A2 (en) 2005-05-25
AU2003271841A1 (en) 2004-03-19
WO2004020631A2 (en) 2004-03-11
CA2496904A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
WO2004020631A3 (en) Genetic suppression and replacement
JP7364472B2 (en) Systems, methods, and compositions for targeted nucleic acid editing
AU2016326711B2 (en) Use of exonucleases to improve CRISPR/Cas-mediated genome editing
Verdel et al. Identification of a new family of higher eukaryotic histone deacetylases: coordinate expression of differentiation-dependent chromatin modifiers
US20230272430A1 (en) Methods and compositions for modulating a genome
JP2023123499A (en) Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
KR20200066616A (en) Systems, methods and compositions for targeted nucleic acid editing
JP7083595B2 (en) Design of rare cut endonucleases that efficiently and specifically target DNA sequences with highly repetitive motifs
KR20180081600A (en) Substances and methods for the treatment of ticin-based diarrhea and other ticinopathies
KR20180069898A (en) Nucleobase editing agents and uses thereof
WO2003080807A8 (en) Compositions and methods for suppressing eukaryotic gene expression
US20230279374A1 (en) Modified cas9 protein, and use thereof
KR102626503B1 (en) Target sequence-specific modification technology using nucleotide target recognition
WO2022092317A1 (en) ENGINEERED Cas12f PROTEIN
JP7001272B2 (en) Method for improving mutation introduction efficiency in genome sequence modification technology, and molecular complex used for it
Jo et al. Therapeutic adenine base editing corrects nonsense mutation and improves visual function in a mouse model of Leber congenital amaurosis
CA2232738A1 (en) Strategy for suppressing the expression of an endogenous gene
Gattoni et al. Modulation of alternative splicing of adenoviral E1A transcripts: factors involved in the early-to-late transition.
JP7133856B2 (en) A method for converting a nucleic acid sequence of a cell, which specifically converts a targeted DNA nucleobase using a DNA-modifying enzyme endogenous to the cell, and a molecular complex used therefor
Kim et al. Cloning and expression of human mitotic centromere-associated kinesin gene
Kuang et al. Advances in base editing with an emphasis on an AAV-based strategy
JPH0670768A (en) Blasticidin s deaminase gene
KR102081962B1 (en) Composition for cleaving amyloid precursor protein gene
Seeberg et al. Repair of alkylation damage to DNA
KR20180128864A (en) Gene editing composition comprising sgRNAs with matched 5' nucleotide and gene editing method using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2496904

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003753679

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003753679

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP